6.24-6.30 | 临床研究顶刊快报
文摘
教育
2024-07-02 10:00
中国香港
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
1. Chehade M, Dellon ES, Spergel JM, Collins MH, Rothenberg ME, Pesek RD, et al. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age. New England Journal of Medicine. 2024;390(24):2239-51.2. Rothenberg ME, Dellon ES, Collins MH, Bredenoord AJ, Hirano I, Peterson KA, et al. Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis. New England Journal of Medicine. 2024;390(24):2252-63.3. Li S, Gu H-Q, Li H, Wang X, Jin A, Guo S, et al. Reteplase versus Alteplase for Acute Ischemic Stroke. New England Journal of Medicine. 2024;390(24):2264-73.4. Bhatt Surya P, Rabe Klaus F, Hanania Nicola A, Vogelmeier Claus F, Bafadhel M, Christenson Stephanie A, et al. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. New England Journal of Medicine. 2024;390(24):2274-83.5. Plotkin SR, Yohay KH, Nghiemphu PL, Dinh CT, Babovic-Vuksanovic D, Merker VL, et al. Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors. New England Journal of Medicine. 2024;390(24):2284-94.6. Newcomb LF, Schenk JM, Zheng Y, Liu M, Zhu K, Brooks JD, et al. Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer. JAMA. 2024;331(24):2084-93.7. Shen L, Lee MMY, Jhund PS, Granger CB, Anand IS, Maggioni AP, et al. Revisiting Race and the Benefit of RAS Blockade in Heart Failure: A Meta-Analysis of Randomized Clinical Trials. JAMA. 2024;331(24):2094-104.8. Iskander R, Moyer H, Vigneault K, Mahmud SM, Kimmelman J. Survival Benefit Associated With Participation in Clinical Trials of Anticancer Drugs: A Systematic Review and Meta-Analysis. JAMA. 2024;331(24):2105-13.9. Bretherton CP, Achten J, Jogarah V, Petrou S, Peckham N, Achana F, et al. Early versus delayed weight-bearing following operatively treated ankle fracture (WAX): a non-inferiority, multicentre, randomised controlled trial. The Lancet. 2024;403(10446):2787-97.10. Raj R, Tommiska P, Koivisto T, Leinonen V, Danner N, Posti JP, et al. Burr-hole drainage with or without irrigation for chronic subdural haematoma (FINISH): a Finnish, nationwide, parallel-group, multicentre, randomised, controlled, non-inferiority trial. The Lancet. 2024;403(10446):2798-806.11. Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. The Lancet. 2024;403(10446):2807-17.12. Conrad N, Molenberghs G, Verbeke G, Zaccardi F, Lawson C, Friday JM, et al. Trends in cardiovascular disease incidence among 22 million people in the UK over 20 years: population based study. BMJ. 2024;385:e078523.13. Li J, Meng X, Shi F-D, Jing J, Gu H-Q, Jin A, et al. Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial. BMJ. 2024;385:e079061. 14. Fu EL, Wexler DJ, Cromer SJ, Bykov K, Paik JM, Patorno E. SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study. BMJ. 2024;385:e078483.部分文字参考新英格兰医学前沿。
